Clinically, VLP-based vaccines against TAA Melan-A have been tested in melanoma patients showing Melan-A/Mart-A specific CD8+ and CD4+ responses in the majority of patients with sustained immune responses lasting more than a year [22]. Here, CD8A is linked to melanoma.